1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,965 | 1,018 | 19:01 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SYNTHAVERSE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 56,60 | +3,06 % | Novonesis (Novozymes A/S): Novonesis delivered 8% organic sales growth in the first nine months of 2025 | Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark - November 6, 2025. Novonesis delivered 8% organic sales growth... ► Artikel lesen | |
| GENMAB | 295,90 | +1,93 % | Genmab A/S: Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence | Supports Genmab's ambition to build an AI-enabled innovation model that advances the company's vision of bringing transformative antibody medicines to patients Genmab A/S (Nasdaq: GMAB) announced... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,978 | -0,45 % | Arbutus Biopharma Corporation: Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech... ► Artikel lesen | |
| VERICEL | 34,600 | +0,58 % | Vericel Corporation: Vericel Reports Third Quarter 2025 Financial Results | Record Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Net Income of $5.1 Million and Adjusted EBITDA Margin of 25% Record Third Quarter Operating Cash Flow... ► Artikel lesen | |
| MOLECULIN BIOTECH | 4,035 | -1,82 % | Moleculin Biotech, Inc. - 8-K, Current Report | ||
| SENSEI BIOTHERAPEUTICS | 11,330 | +2,44 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,694 | -1,40 % | BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI | NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,356 | -9,64 % | MustGrow Biologics Corp.: MustGrow Announces Non-Brokered LIFE Offering of up to $2 Million | Saskatoon, Saskatchewan--(Newsfile Corp. - January 8, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce a non-brokered... ► Artikel lesen | |
| AKEBIA | 1,331 | +3,74 % | Akebia Flat on Kidney Disease Tests | ||
| REGENXBIO | 12,800 | -0,78 % | REGENXBIO Inc.: REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights | RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026
Pivotal trial enrollment... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,150 | -3,38 % | Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA for the Treatment of Niemann-Pick Disease Type C (NPC) | CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 6,800 | +6,25 % | Piper Sandler stuft Fennec Pharmaceuticals mit "Overweight" ein und sieht hohes Kurspotenzial | ||
| REVANCE THERAPEUTICS | 3,420 | 0,00 % | AbbVie wins $56M royalty award from Revance in Botox patent infringement case | ||
| CORVUS PHARMACEUTICALS | 5,880 | -0,84 % | Corvus Pharmaceuticals stock awaits key January 2026 trial data | ||
| CARTESIAN THERAPEUTICS | 7,300 | +14,96 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook | Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential... ► Artikel lesen |
SYNTHAVERSE SA gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,032 (+3,36 %) liegt der Kurs bei 0,984 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNTHAVERSE SA finden Sie auf Wallstreet Online.